ArticleThe American surgeon2016
Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up.
Article in The American surgeon, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Remote skin self-examination training of melanoma survivors and their skin check partners: A randomized trial and comparison with in-person training.Cancer medicine · 2020Trial
- Durable benefits, but no improvements in overall survival: what can we learn from CheckMate 238 after 9 years of follow-up?Translational cancer research · 2026Article
- Survival impact of second primary cutaneous and non-cutaneous melanoma in melanoma survivors.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Primary Cutaneous Melanoma-Management in 2024.Journal of clinical medicine · 2024Article
- Incidence of Second Primary Melanoma in Cutaneous Melanoma Survivors.Annals of surgical oncology · 2022Article
- Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma.The Australasian journal of dermatology · 2022Article
- Multiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital.Journal of clinical medicine · 2022Article
- Melanoma: Staging and Follow-Up.Dermatology practical & conceptual · 2021Review
- Canadian Melanoma Conference Recommendations on High-Risk Melanoma Surveillance: A Report from the 14th Annual Canadian Melanoma Conference; Banff, Alberta; 20-22 February 2020.Current oncology (Toronto, Ont.) · 2021Article
- Skin check partner assistance for melanoma skin self-examination by at-risk patients: it takes two to identify melanomas.Future oncology (London, England) · 2020Article
- Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM).Scientific reports · 2019Article
- Acral Melanoma: A Patient's Experience and Physician's Commentary.Dermatology and therapy · 2018Article
- Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011).Journal of the American Academy of Dermatology · 2018Article
- Systematic Automated Population-Based Surveillance to Improve Outcomes in Primary Cutaneous Melanoma.Journal of primary care & community healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The impact on survival of a second primary melanoma (SPM) is unclear. We used our melanoma center's database to examine clinicopathologic risk factors and outcomes of stage 0 to IV cutaneous melanoma in patients with one versus two primaries. Among 12,325 patients with primary melanoma, 969 (7.86%) developed SPM. SPMs were significantly thinner than autologous primary melanomas (P = 0.01), and 451 SPM patients had better overall and melanoma-specific survival than 451 prognostically matched non-SPM patients (P < 0.0001 and 0.0001, respectively) at a median follow-up of 142.37 months. Patients with cutaneous melanoma are at high risk for development of SPM, but the development of SPM does not seem to impair survival.
Indexed as
Identifiers
27779995PMC5555365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.